These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 11477330

  • 1. Fluorescence polarization immunoassay: can it result in an overestimation of vancomycin in patients not suffering from renal failure?
    Sym D, Smith C, Meenan G, Lehrer M.
    Ther Drug Monit; 2001 Aug; 23(4):441-4. PubMed ID: 11477330
    [Abstract] [Full Text] [Related]

  • 2. Vancomycin serum concentrations in patients with renal dysfunction: a comparison of fluorescence polarization immunoassay and the enzyme-multiplied immunoassay technique.
    Peckman HJ, Dupuis RE, Sawyer WT, Brouwer KL, Cross RE.
    Ther Drug Monit; 1996 Dec; 18(6):647-53. PubMed ID: 8946660
    [Abstract] [Full Text] [Related]

  • 3. Vancomycin assay performance in patients with acute renal failure.
    Trujillo TN, Sowinski KM, Venezia RA, Scott MK, Mueller BA.
    Intensive Care Med; 1999 Nov; 25(11):1291-6. PubMed ID: 10654216
    [Abstract] [Full Text] [Related]

  • 4. Falsely elevated serum vancomycin concentrations in hemodialysis patients.
    Follin SL, Mueller BA, Scott MK, Carfagna MA, Kraus MA.
    Am J Kidney Dis; 1996 Jan; 27(1):67-74. PubMed ID: 8546140
    [Abstract] [Full Text] [Related]

  • 5. New modified fluorescence polarization immunoassay does not falsely elevate vancomycin concentrations in patients with end-stage renal disease.
    Smith PF, Petros WP, Soucie MP, Copeland KR.
    Ther Drug Monit; 1998 Apr; 20(2):231-5. PubMed ID: 9558140
    [Abstract] [Full Text] [Related]

  • 6. Instability of standard calibrators may be involved in overestimating vancomycin concentrations determined by fluorescence polarization immunoassay.
    Morishige H, Shuto H, Ieiri I, Otsubo K, Oishi R.
    Ther Drug Monit; 1996 Feb; 18(1):80-5. PubMed ID: 8848826
    [Abstract] [Full Text] [Related]

  • 7. Assay of vancomycin by fluorescence polarisation immunoassay and EMIT in patients with renal failure.
    Saunders NJ, Want SV, Adams DJ.
    J Antimicrob Chemother; 1995 Aug; 36(2):411-5. PubMed ID: 8522471
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease.
    Somerville AL, Wright DH, Rotschafer JC.
    Pharmacotherapy; 1999 Jun; 19(6):702-7. PubMed ID: 10391415
    [Abstract] [Full Text] [Related]

  • 10. Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients.
    Anne L, Hu M, Chan K, Colin L, Gottwald K.
    Ther Drug Monit; 1989 Sep; 11(5):585-91. PubMed ID: 2683253
    [Abstract] [Full Text] [Related]

  • 11. Abbott AxSYM Vancomycin II assay: multicenter evaluation and interference studies.
    Azzazy HM, Chou PP, Tsushima JH, Troxil S, Gordon M, Avers RJ, Chiappetta E, Duh SH, Christenson RH.
    Ther Drug Monit; 1998 Apr; 20(2):202-8. PubMed ID: 9558135
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Establishment of norvancomycin fluorescence polarization immunoassay for therapeutic drug monitoring.
    Wu XJ, Zhang J, Yu JC, Cao GY, Shi YG, Zhang YY, Wang MG.
    J Antibiot (Tokyo); 2012 Jan; 65(1):35-9. PubMed ID: 22045420
    [Abstract] [Full Text] [Related]

  • 14. Clinical laboratory-based assay methodologies may underestimate and increase variability of vancomycin protein binding in hospitalized patients.
    Crandon JL, MacVane SH, Nicolau DP.
    Pharmacotherapy; 2014 Feb; 34(2):203-9. PubMed ID: 23798336
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of Emit tox benzodiazepine and barbiturate assays on the Vitalab Viva analyser and FPIA on the Abbott ADx analyser.
    Charlier CJ, Plomteux GJ.
    Clin Chem Lab Med; 2000 Jul; 38(7):615-8. PubMed ID: 11028766
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of Innofluor fluorescence polarization immunoassay kits for the determination of serum concentrations of gentamicin, tobramycin, amikacin and vancomycin.lesassays@ukneqasaa.win-uk.net.
    White LO, Holt HA, Reeves DS, MacGowan AP.
    J Antimicrob Chemother; 1997 Mar; 39(3):355-61. PubMed ID: 9096185
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic drug monitoring of vancomycin in severe sepsis and septic shock.
    Vázquez M, Fagiolino P, Boronat A, Buroni M, Maldonado C.
    Int J Clin Pharmacol Ther; 2008 Mar; 46(3):140-5. PubMed ID: 18397685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.